IBRX Stock Cash Flow Statements

ImmunityBio Quarterly Cash Flow Statements Chart

Quarterly

Annual

Stock-Based Compensation

Operating Cash Flow

Investing Cash Flow

Financing Cash Flow

Free Cash Flow

Capital Expenditure

ImmunityBio Quarterly Cash Flow Statements Table

Quarterly

Annual

Unit: USD	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31	2019-12-31	2019-09-30	2019-06-30	2019-03-31	2018-12-31	2018-09-30	2018-06-30	2018-03-31	2017-12-31	2017-09-30	2017-06-30	2017-03-31	2016-12-31	2016-09-30	2016-06-30	2016-03-31	2015-12-31	2015-09-30

operating activities:
net income	-92,574,000	-129,666,000	-59,179,000	-85,752,000	-134,584,000	-134,130,000	-233,414,000	-95,642,000	-138,213,000	-116,583,000	-108,326,000	-111,161,000	-94,835,000	-102,998,000	-91,553,000	-88,429,000	-89,385,000	-80,481,000	-32,132,000	-21,776,000	-20,092,000	-18,383,000	-15,641,000	-15,581,000	-16,682,000	-17,885,000	-17,340,000	-23,635,000	-27,732,000	-27,519,000	-24,487,000	-23,969,000	-23,452,000	-24,515,000	-24,238,000	-31,897,000	-34,024,000	-30,650,000	-76,821,000	-42,649,000
adjustments to reconcile net income to net cash from operating activities:
change in fair value of related-party convertible note	-1,169,000	42,582,000
non-cash interest expense related to revenue interest liability	10,019,000	13,266,000
stock-based compensation expense	9,648,000	9,537,000	9,038,000	7,489,000	9,639,000	8,266,000	12,774,000	14,449,000	11,062,000	10,878,000	9,350,000	10,630,000	10,175,000	10,024,000	10,180,000	13,840,000	17,863,000	15,298,000	667,000	711,000	316,000	445,000	477,000	277,000	522,000	1,351,000	1,407,000	3,968,000	8,934,000	9,073,000	8,884,000	8,714,000	9,381,000	10,018,000	11,266,000	18,669,000	23,382,000	20,535,000	70,554,000	36,103,000
depreciation and amortization	3,880,000	3,829,000	4,138,000	4,455,000	4,406,000	4,555,000	4,564,000	4,585,000	4,682,000	4,681,000	5,226,000	4,500,000	4,444,000	4,090,000	3,595,000	3,687,000	3,984,000	2,972,000	2,283,000	2,380,000	2,267,000	2,217,000	2,209,000	2,202,000	2,206,000	2,395,000	2,787,000	2,776,000	2,369,000	1,623,000	1,569,000	1,461,000	1,374,000	1,162,000	1,839,000	770,000	513,000	485,000	405,000	25,000
change in fair value of derivative liabilities	-1,931,000	-5,578,000	6,607,000	-1,614,000	-21,194,000	2,724,000
change in fair value of warrant liabilities	-3,889,000	448,000	-9,733,000	-31,324,000	19,300,000	1,802,000	79,400,000	-14,265,000	10,019,000	-27,554,000
non-cash lease expense related to operating lease right-of-use assets	905,000	925,000	1,615,000	1,415,000	1,380,000	1,346,000	1,326,000	1,553,000	1,636,000	1,597,000	1,652,000	1,475,000	1,487,000	1,318,000	1,384,000	1,231,000	714,000	1,555,000	1,140,000	968,000	648,000	674,000	679,000	659,000
non-cash lease expense related to operating lease right-of-use assets – related parties	678,000	658,000
non-cash interest items	-62,000	-62,000	1,337,000	-62,000	-62,000	-63,000	201,000	3,962,000	2,521,000	2,505,000	-2,024,000	6,848,000	3,524,000	3,398,000			2,813,000	3,435,000	37,000	-398,000	93,000	17,000	73,000	110,000	158,000	-95,000	-32,000	232,000	-58,000	149,000	72,000	178,000	217,000	253,000	-300,000	243,000	-221,000	-295,000
transaction costs allocated to warrant liabilities							0	1,026,000	0	984,000
accretion of discounts on marketable debt securities	-11,000	-52,000	-24,000	-580,000	-394,000	-491,000
amortization of related-party notes discounts			5,007,000	6,199,000	5,832,000	5,549,000	7,118,000	11,454,000	12,288,000	11,536,000
other	211,000	242,000	-37,000	52,000	20,000	74,000	52,000	-582,000	12,000	111,000	400,000	-152,000	-823,000	848,000				-125,000
changes in operating assets and liabilities:
accounts receivable	-5,097,000	-14,669,000	1,815,000	-3,142,000																																			0	-25,000
inventories	1,804,000	-172,000	-6,314,000	-147,000
prepaid expenses and other current assets	-3,939,000	114,000	1,333,000	-2,778,000	1,514,000	1,634,000	-3,505,000	-1,777,000	1,551,000	9,689,000	-2,137,000	54,000	-14,256,000	-218,000	-2,674,000	-4,995,000	6,354,000	-934,000	963,000	-3,218,000	683,000	244,000					2,634,000	-11,908,000	303,000	-847,000	732,000
prepaid expenses – related parties	-205,000	951,000
other assets	1,227,000	-84,000	-1,034,000	-255,000	49,000	132,000	528,000	338,000	752,000	295,000		1,439,000	598,000	101,000		-645,000	-4,892,000	693,000	-455,000	-51,000	-168,000	335,000					66,000	-1,229,000			-6,000	12,000	326,000	126,000	78,000	237,000	175,000	-337,000	-33,000	2,431,000
accounts payable	-6,216,000	6,439,000	-3,214,000	-8,922,000	4,655,000	4,314,000	-2,877,000	-2,730,000	-1,537,000	668,000	437,000	1,028,000	5,740,000	795,000	-3,547,000	-2,770,000	-3,897,000	6,497,000	-2,111,000	3,078,000	-95,000	1,270,000	-301,000	407,000	-735,000	670,000	-1,034,000	-1,941,000	1,758,000	117,000	-1,343,000	2,560,000	-1,792,000	725,000	567,000	237,000	821,000	-737,000	-3,188,000	1,767,000
accrued expenses and other liabilities	8,723,000	-12,933,000	-2,114,000	6,226,000	3,297,000	-8,917,000	-19,516,000	-1,659,000	9,274,000	18,590,000	-3,151,000	6,651,000	-10,289,000	10,891,000	4,558,000	4,445,000	-1,928,000	-1,893,000	2,112,000	103,000	474,000	997,000	-398,000	843,000	-13,262,000	797,000	-1,911,000	14,016,000	-1,275,000	1,878,000	147,000	658,000	-1,538,000	434,000	-327,000	816,000	402,000	1,236,000
due to and due from related parties	-7,000	51,000
operating lease liabilities	-992,000	-916,000	-1,537,000	-1,516,000	-1,522,000	-898,000	-549,000	-1,108,000	190,000	-1,511,000	-2,013,000	-112,000	-1,855,000	-339,000	-517,000	-670,000	-1,503,000	-1,474,000	-1,287,000	-1,118,000	-778,000	-758,000	-737,000
operating lease liabilities – related parties	-852,000	-816,000
net cash from operating activities	-79,746,000	-85,905,000	-85,144,000	-98,763,000	-100,347,000	-106,982,000	-115,271,000	-87,403,000	-79,773,000	-84,310,000	-90,727,000	-80,600,000	-91,252,000	-74,930,000	-71,639,000	-72,716,000	-69,595,000	-60,469,000	-23,056,000	-18,280,000	-16,521,000	-12,596,000	-14,885,000	-16,572,000	-16,827,000	-13,078,000	-14,033,000	-17,571,000	-16,266,000	-15,511,000	-13,640,000	-10,133,000	-14,950,000	-10,057,000	-10,753,000	-10,683,000	-8,301,000	-8,856,000	-11,085,000	-4,178,000
capex	-1,081,000	-1,121,000	-2,111,000	-2,792,000	-724,000	-1,261,000	-7,955,000	-5,675,000	-8,526,000	-8,428,000	-18,931,000	-15,935,000	-15,949,000	-27,347,000	-10,403,000	-8,032,000	-8,045,000	-7,083,000	-401,000	-1,698,000	-394,000	-146,000	-680,000	-413,000	-985,000	-2,104,000	-2,045,000	-3,663,000	-2,492,000	-4,902,000	-11,433,000	-10,717,000	-8,156,000	-4,509,000	0	-3,079,000	-1,056,000	-1,067,000	-955,000	-1,134,000
free cash flows	-80,827,000	-87,026,000	-87,255,000	-101,555,000	-101,071,000	-108,243,000	-123,226,000	-93,078,000	-88,299,000	-92,738,000	-109,658,000	-96,535,000	-107,201,000	-102,277,000	-82,042,000	-80,748,000	-77,640,000	-67,552,000	-23,457,000	-19,978,000	-16,915,000	-12,742,000	-15,565,000	-16,985,000	-17,812,000	-15,182,000	-16,078,000	-21,234,000	-18,758,000	-20,413,000	-25,073,000	-20,850,000	-23,106,000	-14,566,000	-10,753,000	-13,762,000	-9,357,000	-9,923,000	-12,040,000	-5,312,000
investing activities:
purchases of marketable debt securities, available-for-sale	-15,061,000	-100,000	-6,089,000	0	-85,766,000	-48,363,000	-166,000	-9,956,000	-78,000	-158,000	-19,000	-86,000	-125,000	-34,082,000	-139,001,000	-2,483,000	-175,000	-91,000	-5,991,000	-70,791,000	-4,490,000	-10,300,000	-9,787,000	-10,042,000	-16,516,000	-50,273,000	-12,513,000	-28,754,000
proceeds from maturities of marketable debt securities, available-for-sale	0	5,350,000	18,034,000
purchases of property, plant and equipment	-1,081,000	-1,121,000	-2,111,000	-2,792,000	-724,000	-1,261,000	-7,955,000	-5,675,000	-8,526,000	-8,428,000	-18,931,000	-15,935,000	-15,949,000	-27,347,000	-10,403,000	-8,032,000	-8,045,000	-7,083,000	-401,000	-1,698,000	-394,000	-146,000	-680,000	-413,000	-985,000	-2,104,000	-2,045,000	-3,663,000	-2,492,000	-4,902,000	-11,433,000	-10,717,000	-8,156,000	-4,509,000
proceeds from sales of marketable debt securities				20,040,000														7,094,000
net cash from investing activities	-16,142,000	4,129,000	9,834,000	65,032,000	-51,490,000	-35,622,000	2,249,000	-15,631,000	-8,604,000	-8,484,000	-18,894,000	-1,168,000	116,672,000	-69,313,000	-137,802,000	10,582,000	10,489,000	31,845,000	6,568,000	-56,247,000	14,927,000	14,163,000	12,163,000	17,374,000	11,378,000	-19,459,000	15,914,000	16,874,000	21,393,000	2,920,000	19,734,000	6,961,000	56,819,000	16,038,000	-8,464,000	6,855,000	-10,151,000	-101,912,000	-171,979,000	-672,000
financing activities:
proceeds from equity offerings, net of discounts and issuance costs			107,732,000	0			15,920,000	37,463,000	-110,000	47,288,000
net share settlement for rsus vesting	-322,000	-1,202,000	-803,000	-299,000	-496,000	-3,867,000	-1,562,000	-1,464,000	-60,000	-357,000	-219,000	-10,000	-15,000	-372,000		-960,000	0	-2,624,000
proceeds from exercises of stock options	0	220,000	0	286,000			1,000	32,000	135,000	126,000	0	0	0	74,000	351,000	678,000	3,311,000	1,121,000	259,000	353,000
principal payments of finance leases			0	-22,000	-21,000	-21,000	-20,000	-19,000	-19,000	-19,000	-18,000
proceeds from the ripa, net of issuance costs			0	0
proceeds from exercises of warrants			0	15,617,000	43,548,000	14,116,000
proceeds from exercise of oberland stock option, net of commissions			0	0
net cash from financing activities	172,810,000	-982,000	106,929,000	15,582,000	148,894,000	10,225,000	200,539,000	237,502,000	43,412,000	76,888,000	109,940,000	123,986,000	-15,000	-298,000	325,953,000	42,656,000	98,337,000	38,497,000	241,000	-483,000	87,340,000	-123,000	-61,000	-40,000	-501,000	39,195,000	-370,000	-115,000	-201,000	-85,000	-3,142,000	-14,947,000	-16,426,000	-468,000	-4,104,000	-2,991,000	-6,575,000	-1,890,000	306,000	243,079,000
effect of exchange rate changes on cash and cash equivalents, and restricted cash	76,000	-10,000	-7,000
net change in cash and cash equivalents, and restricted cash	76,998,000	-82,768,000	31,612,000
cash and cash equivalents, and restricted cash, beginning of period	0	143,912,000
cash and cash equivalents, and restricted cash, end of period	76,998,000	61,144,000
unrealized losses (gains) on equity securities		1,000
payment of revenue interest liability						-3,000
change in fair value of convertible note							36,952,000	-7,517,000
non-cash interest expense related to the revenue interest liability			10,289,000	10,504,000	9,207,000	8,004,000
unrealized losses on equity securities			112,000	505,000
impairment of intangible assets											0
impairment of fixed assets
related parties			223,000	484,000	214,000	-158,000	170,000	-67,000	-1,171,000	-61,000	414,000	2,220,000	-2,241,000	-1,618,000	-5,473,000	-7,293,000	-18,000	2,597,000
proceeds from sales of marketable debt and equity securities							270,000	0	0	102,000	56,000	99,000			195,000	-1,000
acquisition of a business, net of transaction costs			0
cash paid for other investments			0
purchase of intangible assets											0	0	0	-21,229,000
investment in joint venture – an equity method investment											0	0	0	-1,000,000
proceeds from issuance of related-party promissory notes net of issuance costs paid
proceeds from stock issuance in connection with the ripa, net of transaction costs
payment for contingent consideration											0				0
cash and cash equivalents, and restricted cash, beginning of year
cash and cash equivalents, and restricted cash, end of year
proceeds from issuance of related-party promissory notes, net of issuance costs paid								199,000,000			49,750,000
maturities of marketable debt securities, available-for-sale					35,000,000	13,021,000
effect of exchange rate changes on cash, cash equivalents, and restricted cash					12,000	-39,000	-27,000	-1,000	-10,000	-254,000	161,000	43,000	255,000	-175,000	65,000	44,000	48,000	-109,000
net change in cash, cash equivalents, and restricted cash					-2,931,000	-132,418,000	87,490,000	134,467,000	-44,975,000	-16,160,000	480,000	42,261,000	25,660,000	-144,716,000	116,577,000	-19,434,000	39,279,000	9,764,000
cash, cash equivalents, and restricted cash, beginning of period					0	265,787,000		0	0	104,965,000		0	0	181,280,000		0	0	35,094,000		0	0	15,687,000
cash, cash equivalents, and restricted cash, end of period					-2,931,000	133,369,000		134,467,000	-44,975,000	88,805,000		42,261,000	25,660,000	36,564,000		-19,434,000	39,279,000	44,858,000		-75,010,000	85,746,000	17,131,000		762,000	-5,950,000	23,658,000	1,511,000	-812,000
unrealized (gains) on equity securities						-725,000				-135,000
proceeds from sale of marketable debt securities						981,000
amortization of premiums, net of discounts, on marketable debt securities
proceeds from sales of property, plant and equipment															0												392,000
maturities of marketable debt securities, available for sale											0	14,754,000	99,089,000	14,345,000	11,407,000	600,000
proceeds from the ripa, net of transaction costs
sale of assets to an entity under common control															0
cash, cash equivalents, and restricted cash, beginning of year
cash, cash equivalents, and restricted cash, end of year
amortization of net premiums, net of discounts, on marketable debt securities
issuance of common stock under “at-the-market” offering, net of offering costs								2,490,000
proceeds from issuance of related-party convertible promissory notes, net of issuance costs paid										29,850,000
change in fair value of warrant liability
transaction costs allocated to warrant liability
unrealized loss on non-marketable equity investment
deferred tax
investment and other assets
amortization of net premiums and discounts on marketable debt securities												10,000				13,000	23,000	225,000	369,000	334,000	46,000	45,000
unrealized (gains) losses on equity securities																		-8,834,000
proceeds from equity offering, net of issuance costs paid															27,582,000	41,922,000				-514,000
loss on equity method investment													3,900,000	197,000
unrealized gains on equity securities														-1,419,000		6,008,000
payment to precision biologics to facilitate deconsolidation
purchase of non-marketable equity investment
net share settlement for rsus vesting and warrant exercise
repurchase of common stock																								0										-1,050,000	-3,949,000	-2,574,000	-6,774,000	-2,550,000		0
non-cash interest expense
realized gains on sales of equity securities																0
change in fair value of contingent consideration
proceeds from issuance of related-party promissory notes																0	0	40,000,000
change in fair value of contingent consideration obligations
maturities of marketable debt securities																		31,925,000	11,270,000
unrealized loss on equity investment
losses (gains) on sales of marketable debt securities
loss on disposal of assets																											75,000	44,000	54,000	36,000	0				0	0	3,000	15,000
loss on impairment of assets
deferred income tax benefit																											-122,000	-128,000	-124,000	-124,000	-182,000	-98,000	-124,000	-93,000	-152,000	-50,000	-228,000	-145,000
due to related parties																			3,943,000	705,000	86,000	300,000	-254,000	-157,000	-520,000	-162,000	-503,000	326,000	-528,000	20,000	803,000	-670,000	115,000	1,314,000	-123,000	126,000	53,000	322,000	742,000
deferred rent																																				619,000	531,000	500,000	508,000
purchases of debt securities, held-to-maturity																											0
purchases of investments in equity securities
sales of marketable debt securities																			1,690,000
proceeds from equity offering, net of issuance cost paid
principal payments of financing obligations																														-65,000
repurchases of common stock with commissions
net share settlement for restricted stock unit vesting and warrant and option exercises
net decrease in cash, cash equivalents, and restricted cash
cash, cash equivalents and restricted cash, beginning of period																							0	0	0	17,000,000	0	0	0	24,051,000
cash, cash equivalents and restricted cash, end of period																														11,375,000
loss on sales of marketable debt securities																						1,000
loss on impairment of fixed assets
purchase of viracta common stock																								0
net share settlement for restricted stock unit vesting
net increase in cash, cash equivalents, and restricted cash																				-75,010,000	85,746,000	1,444,000	-2,783,000	762,000	-5,950,000	6,658,000	1,511,000	-812,000
operating lease right-of-use assets																							0	-553,000	0	-247,000
sales/maturities of marketable debt securities																					19,811,000	24,609,000	22,630,000	27,829,000	28,882,000	32,918,000	30,080,000	49,633,000	45,711,000	39,860,000
net share settlement for restricted stock unit vesting and option exercises																					-40,000	-123,000
proceeds from exercises of stock options and warrants
gains on sales of marketable debt securities
deferred rent and revenue																											-138,000	-131,000	-121,000	-118,000	-121,000	-105,000	1,467,000	-40,000
principal payments of financing/capital lease obligations																											-142,000	-137,000			-64,000	-14,948,000
loss on impairment and loss on disposal of assets																								0
prepaid expenses, other current assets and other assets																								-4,642,000	10,769,000	88,000
purchase of debt securities, held-to-maturity
principal payments of financing lease obligations
proceeds from exercise of stock options and warrants																								0	0	39,221,000	0	22,000	12,000	23,000		1,000	37,000	1,154,000				660,000
net share settlement for rsu vesting, and option and warrant exercises																								-40,000
reconciliation of cash, cash equivalents, and restricted cash at end of period:
cash and cash equivalents																								1,012,000	-5,000,000	22,279,000	1,511,000	-812,000	4,926,000	11,196,000
restricted cash																								-250,000	-950,000	1,379,000
supplemental disclosure of cash flow information:
cash paid during the period for:
interest																								5,000	0	3,000	258,000	38,000	145,000	34,000	36,000	394,000	201,000	37,000	37,000
income taxes																								0			0	0			0	0			1,000	0	0	1,000	-5,000	5,000
supplemental disclosure of non-cash investing and financing activities:
property and equipment purchases included in accounts payable, accrued expenses, and other liabilities																								-1,120,000	-723,000	2,031,000	227,000	-2,267,000
conversion of viracta convertible notes and accrued interest into investment in equity securities of viracta																								0	0	751,000
unrealized gains on marketable debt securities																								31,000	122,000	118,000	90,000
cashless exercise of stock options and warrants																								0							0				0	0
amortization of net premiums on marketable debt securities																									-40,000	41,000	81,000	39,000	142,000	201,000
operating lease liability, less current portion																									-754,000	-655,000
amortization of operating lease right-of-use assets																										624,000
net share settlement for rsu vesting and option exercises																										-26,000		0	-80,000	-43,000	-330,000	0	-159,000	-550,000
cashless exercise of stock options																										29,000
gain on sales of marketable debt securities
purchase of investment in equity securities
repurchase of common stock with commissions																																0
restricted cash included in other assets																											0	0	0	179,000
property and equipment purchases acquired under capital lease																															0	0
estimated fair value of building under build-to-suit lease
lease incentive with a related party
purchase of equity investment
cashless exercise of warrants																												93,000											-230,000	807,000
cash, cash equivalents, and restricted cash at end of period
property and equipment purchases acquired under capital lease expenses
unrealized gain on marketable debt securities																													107,000	-174,000
purchases of marketable debt securities																														-32,038,000
net increase in cash, cash equivalents and restricted cash																														-12,676,000
reconciliation of cash, cash equivalents and restricted cash at end of period:
cash, cash equivalents and restricted cash at end of period																														11,375,000
property and equipment purchases included in accounts payable and accrued expenses																														5,930,000		4,159,000	10,910,000	2,492,000		-967,000	985,000	1,074,000
amortization of net premiums on marketable securities																															299,000	358,000	368,000	572,000	615,000	624,000	517,000	426,000
gain on sales of marketable securities																															-7,000	-26,000			-19,000	-49,000	-23,000	-46,000
change in value of warrant liability
loss incurred by inex bio																																							-1,000	0
gain on settlement of note payable																																							0	0
purchase of cost method investment																															0	0	0	-8,500,000
purchases of marketable securities																															-36,240,000	-28,597,000	-21,311,000	-25,207,000	-65,108,000	-42,054,000	-54,440,000	-111,397,000
sales/maturities of marketable securities																															67,407,000	46,275,000	86,286,000	54,254,000	58,002,000	51,988,000
purchase of inex bio inc., net of cash acquired																																								0
proceeds from exercise of stock options																																							35,000	75,000
proceeds from exercise of warrants																																							8,000	206,000
proceeds from equity offerings, net of issuance costs																																							263,000	245,213,000
repayments of notes payable
net increase in cash and cash equivalents																															2,952,000	-18,119,000	25,443,000	5,513,000	-23,321,000					238,179,000
cash and cash equivalents, beginning of period																															0	0	0	8,083,000	0	0	0	175,908,000		0
cash and cash equivalents, end of period																															2,952,000	-18,119,000	25,443,000	13,596,000	-23,321,000	-6,819,000	-25,027,000	63,250,000		238,179,000
unrealized loss on marketable securities
estimated fair value of buildings under build-to-suit leases																																			0
issuance of warrants in inex bio, inc. acquisition																																								0
unrealized gain on marketable securities																																34,000	4,000	70,000	-608,000	-456,000	166,000	796,000
lease incentive
receivables, net, prepaid expenses and other current assets
prepaid and other current assets																																		-13,000		-1,025,000	-195,000	-160,000
principal payments of financing obligation																																		-22,000
amortization of finance issuance costs
amortization of debt discount
forgiveness of note receivable from related party
bad debt expense
accounts receivable, prepaid and other current assets
proceeds from exercise of class b common stock
conversion of debt and payables into common stock
conversion of debt into series c preferred stock
change in par value from 0.001 to 0.0001
conversion of accounts payable against note receivable related party
property, plant and equipment purchases included in accounts payable and accrued expenses
deferred revenue																																				-6,000	-4,000	-5,000	-7,000	-6,000
purchases of property and equipment																																				-3,079,000	-1,056,000	-1,067,000	-955,000	-1,134,000
proceeds from debt and equity offerings, net of issuance costs
repayments of financing obligations
employee payroll taxes paid related to net share settlement of restricted stock units																																							0
effect of exchange rate changes on cash and cash equivalents
lease incentives
investment in intangible assets																																								462,000
payments on notes payable																																							0	0
net decrease in cash and cash equivalents																																					-25,027,000	-112,658,000
sales of marketable securities																																						10,552,000
operating activities
amortization of premiums on marketable securities
notes receivable from related party
other current assets
investing activities
purchase of inex bio, inc., net of cash acquired
financing activities
repurchase of stock
net increase in cash
cash and cash equivalents, beginning of year
cash and cash equivalents, end of year
supplemental disclosure of cash flow information
issuance of warrants in inex bio acquisition
notes received for purchase of class b common stock
estimated fair market value of building under build-to-suit lease
cash flows used in operating activities:
change in fair value of warrant derivative liability																																								0
change in value of note payable
changes in operating assets and liabilities, net of effects of acquisition:
accrued expenses																																								-1,492,000
cash flows used in investing activities:
cash flows from financing activities:
conversion of debt into preferred series c stock
finance issuance costs

We provide you with 20 years of cash flow statements for ImmunityBio stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of ImmunityBio stock. Explore the full financial landscape of ImmunityBio stock with our expertly curated income statements.

The information provided in this report about ImmunityBio stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.